Press release
IgA Nephropathy Therapeutic Market Expected to Witness Robust Growth By 2034, Fueled by Recent FDA Approvals and Clinical Trials Updates | DelveInsight
IgA Nephropathy Market Insight, Epidemiology, And Market Forecast - 2034
DelveInsight's "IgA Nephropathy Market Insight, Epidemiology And Market Forecast - 2034 [https://www.delveinsight.com/report-store/iga-nephropathy-igan-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]" report provides an extensive analysis of IgA nephropathy, including historical and forecasted epidemiology data, current treatment practices, emerging therapies, and market projections across the 7MM (United States, Germany, France, Italy, Spain, United Kingdom, and Japan).
The report indicates that the IgA Nephropathy market is anticipated to grow at a robust CAGR of more than 30% from approximately USD 730 million across 7MM in 2024, driven by increasing disease awareness, improved diagnostic capabilities, and the launch of novel therapeutic options targeting specific pathways involved in IgAN pathogenesis.
This market expansion highlights the increasing awareness of IgAN as a major contributor to end-stage renal disease (ESRD) worldwide, as well as the urgent need for effective disease-modifying treatments beyond traditional supportive care. The growth is further fueled by the introduction of innovative therapies, including Povetacicept, Atacicept, Zigakibart, and ULTOMIRIS, among others.
IgA nephropathy, also known as Berger disease, is a chronic kidney disorder characterized by the deposition of immunoglobulin A (IgA) antibodies in the glomeruli-the tiny filtering units within the kidneys. This abnormal buildup triggers inflammation and progressive damage, impairing the kidneys' ability to filter waste and excess fluid from the blood. Over time, IgA nephropathy can lead to chronic kidney disease or even kidney failure in a significant subset of patients, making it one of the most common causes of glomerulonephritis worldwide.
Download the IgA nephropathy market report to understand which factors are driving the IgA nephropathy therapeutic market @ IgA Nephropathy Market Trends [https://www.delveinsight.com/sample-request/iga-nephropathy-igan-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].
According to DelveInsight's epidemiological analysis, the total diagnosed prevalent population of IgA Nephropathy in the 7MM comprised approximately 415K cases in 2024. Japan accounted for the highest proportion of IgAN diagnosed prevalent cases, with nearly 175K cases. Furthermore, the data reveals a notable gender disparity, with IgA nephropathy showing male predominance in 2024. This epidemiological profile underscores the substantial patient population that could benefit from emerging targeted therapies, thereby driving market growth in the forecast period.
Discover evolving trends in the IgAN patient pool forecasts @ IgAN Epidemiology Analysis [https://www.delveinsight.com/sample-request/iga-nephropathy-igan-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].
Recent Developments in IgA Nephropathy Landscape:
*
In April 2025, Novartis announced that the FDA has granted accelerated approval for VANRAFIA (atrasentan), an oral endothelin A receptor antagonist, to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid progression (UPCR greater than or equal to 1.5 g/g). Vanrafia is taken once daily alongside standard supportive care.
*
In April 2025, Vera Therapeutics completed full enrollment in the pivotal ORIGIN Phase III trial evaluating atacicept in patients with IgAN.
*
In May 2025, Otsuka and OPDC announced that the FDA has accepted the Biologics License Application for sibeprenlimab, an investigational antibody targeting APRIL, for the treatment of adults with IgA nephropathy.
Discover recent advancements in the IgA Nephropathy treatment landscape @ IgA Nephropathy Recent Developments [https://www.delveinsight.com/sample-request/iga-nephropathy-igan-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].
The DelveInsight report also analyses the current and emerging treatment landscape. Currently, only a few drugs have been approved for IgAN treatment, including VANRAFIA (Atrasentan) and FABHALTA (Iptacopan) by Novartis, FILSPARI (Sparsentan) by Travere Therapeutics, and TARPEYO/KINPEYGO (budesonide) by Asahi Kasei (Calliditas Therapeutics), among others.
The IgA nephropathy pipeline is robust, featuring multiple promising candidates in late-stage development that target various pathophysiological mechanisms. Current clinical development programs focus on innovative approaches, including complement pathway inhibition, B-cell modulation, targeted immunosuppression, and novel anti-inflammatory agents. These emerging therapies address the multifaceted nature of IgAN pathogenesis and offer improved efficacy, safety profiles, and quality of life outcomes compared to conventional treatments. The diversification of therapeutic approaches reflects growing understanding of the complex immunological mechanisms underlying IgAN and represents a paradigm shift toward precision medicine in nephrology.
The IgA nephropathy treatment landscape has witnessed significant advancements in recent years, with several breakthrough approvals reshaping clinical practice and further expanding this significant market. In September 2024, Travere Therapeutics achieved a major milestone with the full FDA approval of FILSPARI to slow the decline in kidney function in adults with primary IgA nephropathy. This approval followed an earlier accelerated approval based on proteinuria reduction, with full approval supported by positive long-term data from the PROTECT Study demonstrating sustained clinical benefits. Additionally, FILSPARI received conditional marketing authorization from the European Commission in April 2024 for treating adults with primary IgAN with significant proteinuria.
Discover evolving trends in the IgA Nephropathy treatment landscape @ IgA Nephropathy Therapies Market [https://www.delveinsight.com/sample-request/iga-nephropathy-igan-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].
Despite therapeutic advances, significant unmet needs persist in the IgA nephropathy treatment landscape. These include the need for earlier disease detection, biomarkers to predict disease progression and treatment response, and therapies that can reverse existing kidney damage rather than merely slowing disease progression. Moreover, improving access to specialized care and novel therapies remains challenging, particularly in regions with limited healthcare resources. DelveInsight's analysis highlights that addressing these unmet needs will be crucial for optimizing patient outcomes and maximizing the market potential for emerging IgAN therapies.
Looking ahead, the IgA nephropathy market is expected to witness transformative growth. The integration of biomarkers into clinical practice and the development of combination therapeutic strategies targeting multiple pathways simultaneously represent promising future directions. Additionally, ongoing research into the genetic and molecular determinants of IgAN susceptibility and progression may pave the way for personalized treatment approaches, further revolutionizing the management of this chronic kidney disease and enhancing long-term patient outcomes across the global IgAN landscape.
Table of Contents
1. Key Insights
2. Report Introduction
3. IgAN Market Overview at a Glance
4. Executive Summary
5. Key Events
6. Disease Background and Overview
7. Methodology
8. IgAN Epidemiology and Patient Population
9. IgAN Patient Journey
10. IgAN Marketed Drugs
11. IgAN Emerging Drugs
12. IgAN - 7MM Market Analysis
13. KOL Views
14. IgAN Unmet Needs
15. SWOT Analysis
16. Market Access and Reimbursement
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight
About DelveInsight
DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=iga-nephropathy-therapeutic-market-expected-to-witness-robust-growth-by-2034-fueled-by-recent-fda-approvals-and-clinical-trials-updates-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release IgA Nephropathy Therapeutic Market Expected to Witness Robust Growth By 2034, Fueled by Recent FDA Approvals and Clinical Trials Updates | DelveInsight here
News-ID: 4125272 • Views: …
More Releases from ABNewswire
Understanding Magnetic Switches: Types, Working Principles, and Applications
A magnetic switch is a versatile electrical device that operates by responding to magnetic fields. From Hall Effect to reed switches, explore their functions, types, and diverse applications.
What is a Magnetic Switch?
A magnetic switch is an electrical device that operates by responding to the presence of a magnetic field. It functions by closing or opening its contacts based on the strength of the magnetic field. Specifically, the switch remains closed…
Innovating embedded downlight technology: Leading the global trend of intelligen …
The strong rise of China's manufacturing industry has profoundly reshaped the technological landscape and development trajectory of embedded downlights. With its unparalleled industrial chain advantages, continuous technological innovation, and significant cost-effectiveness, Chinese enterprises have risen from participants in the global lighting industry to undisputed leaders. This transformation goes far beyond the huge production scale; it lies in the thorough innovation of the core technical content and application boundaries of embedded…
North China Electric Power University Foreign Aid Training Program Visits Yiyuan …
On July 23, 2025, the Electrical Industry Training Program of North China Electric Power University's Foreign Aid Project visited Yiyuan Technology for an exchange visit. The purpose was to gain in-depth insights into the company's innovations in renewable energy technology promotion and application [https://www.yiyen.com/about/], and to build bridges connecting university-enterprise cooperation with foreign aid initiatives.
Image: https://ecdn6.globalso.com/upload/p/1108/image_other/2025-07/scene-1.jpg
Image: https://ecdn6.globalso.com/upload/p/1108/image_other/2025-07/scene-3.jpg
Upon arrival, the delegation received a warm welcome from company leadership and the reception…
Pure Sine Wave Low Frequency Inverter Charger
Pure sine wave low frequency inverter [https://www.yiypower.com/ap-mini-600w-1500w-120v-low-frequency-pure-sine-wave-inverter-charger-product/] is widely used and suitable for a variety of scenarios. In terms of home backup power, it can provide reliable power during power outages, ensuring that essential appliances such as refrigerators, air conditioners and medical equipment continue to operate . For solar power generation systems, Inverter charger [https://www.yiypower.com/ap-mini-600w-1500w-120v-low-frequency-pure-sine-wave-inverter-charger-product/] can converter DC Power from Battery, which charged by solar panels, into clean alternating current…
More Releases for IgA
IgA Nephropathy Pipeline 2025: MOA, ROA, FDA-Approved Drugs, and Clinical Trial …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, IgA Nephropathy pipeline constitutes 25+ key companies continuously working towards developing 30+ IgA Nephropathy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"IgA Nephropathy Pipeline Insight, 2025 [https://www.delveinsight.com/sample-request/iga-nephropathy-igan-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the IgA Nephropathy Market.
The IgA Nephropathy Pipeline report…
Multiplier Strengthens Identity Governance with Advanced IGA Solutions
Image: https://www.abnewswire.com/upload/2025/08/8c79c8224ecce453d70ad648fa16d5e9.jpg
Introduction
In today's rapidly evolving digital landscape, managing user identities and access rights has become a critical concern for businesses of all sizes. As organizations expand, ensuring the right individuals have the correct access to systems and data is essential for operational efficiency and security. Multiplier, a leader in innovative enterprise solutions, is empowering companies with comprehensive Identity Governance and Administration (IGA) solutions to address these challenges.
IGA Solutions: The Heart…
IgA Nephropathy Market Positioned for Accelerated Development Through 2032, Delv …
The Key IgA Nephropathy Companies in the market include - Travere Therapeutics, Asahi Kasei (Calliditas Therapeutics), Vertex Pharmaceuticals, Vera Therapeutics, Visterra, Chinook Therapeutics, Novartis, IgA proteases Selecta Biosciences, Shanghai Alebund Pharmaceuticals, Rohto Pharmaceutical, Wuhan Createrna Science and Technology, Guangdong Hengrui Pharmaceutical, LRx Ionis Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd., Travere Therapeutics, and others.
DelveInsight's "IgA Nephropathy Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the IgA Nephropathy,…
IgA Nephropathy Market to Reach New Heights in Growth by 2034, DelveInsight Pred …
The Key IgA Nephropathy Companies in the market include - Travere Therapeutics, Asahi Kasei (Calliditas Therapeutics), Vertex Pharmaceuticals, Vera Therapeutics, Visterra, Chinook Therapeutics, Novartis, IgA proteases Selecta Biosciences, Shanghai Alebund Pharmaceuticals, Rohto Pharmaceutical, Wuhan Createrna Science and Technology, Guangdong Hengrui Pharmaceutical, LRx Ionis Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd., Travere Therapeutics, and others.
DelveInsight's "IgA Nephropathy Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the IgA Nephropathy,…
IgA Nephropathy Drugs Market Trends And Forecast 2023-2030
Innovations and Growth Propel IgA Nephropathy Drugs Market:
Global IgA Nephropathy Drugs Market Expands with Technological Advancements and Research Initiatives
The IgA nephropathy drugs market is witnessing a surge in product launches driven by advancements in technology and an upswing in research and development activities. IgA nephropathy, an autoimmune disease affecting the kidneys, results in inflammation and kidney damage due to the accumulation of antibody clumps. The market is experiencing notable growth,…
IgA Nephropathy Drugs Market Sales, Demands and Forecasts
The IgA Nephropathy Drugs market research report is proficient and top to bottom research by specialists on the current state of the industry. This statistical surveying report gives the most up to date industry information and industry future patterns, enabling you to distinguish the items and end clients driving income development and benefit. It centres around the real drivers and restrictions for the key players and present challenge status with…
